IGF2 activation of HER2 receptor in HER2 positive breast cancer cell lines

被引：0
|
作者：
Helu, Xousaen M. [1 ]
De Leon, Daisy D. [1 ]
机构：
[1] Loma Linda Univ, Loma Linda, CA 92350 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-3925
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3925
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HER2 positive breast cancer
    Gianni, Luca
    Bianchini, Giampaolo
    CANCER RESEARCH, 2023, 83 (05)
  • [2] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
  • [3] Kinomic Profiling Identifies Pathways of HER2 Targeted Therapy Resistance in HER2 Positive Breast Cancer Cell Lines
    Anderson, J.
    Duarte, C.
    Naji, F.
    Bouwmeester, R.
    Rohrbach, T.
    de Wijn, R.
    Willey, C. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S23 - S23
  • [4] Inhibition of HER2 and IGF2 triggers cell death in trastuzumab-resistant HER2 positive JIMT1 cells
    Helu, Xousaen M.
    De Leon, Daisy
    CANCER RESEARCH, 2014, 74 (19)
  • [5] HER2 T cell dependent bispecific antibody (HER2-TDB) for treatment of HER2 positive breast cancer
    Junttila, Teemu T.
    Li, Ji
    Johnston, Jennifer
    Hristopoulos, Maria
    Clark, Robyn
    Ellerman, Diego
    Wang, Bu-Er
    Li, Yijin
    Mathieu, Mary
    Li, Guangmin
    Young, Judy
    Luis, Elizabeth
    Phillips, Gail Lewis
    Stefanich, Eric
    Spiess, Cristoph
    Polson, Andrew
    Irving, Bryan
    Scheer, Justin M.
    Junttila, Melissa R.
    Dennis, Mark S.
    Kelley, Robert
    Totpal, Klara
    Ebens, Allen
    CANCER RESEARCH, 2015, 75
  • [6] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
  • [7] IMMUNOTHERAPY FOR HER2 POSITIVE BREAST CANCER
    Vaidya, T. R.
    Ait-Oudhia, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S20 - S20
  • [8] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04): : 535 - 540
  • [9] Her2 positive breast cancer: practices
    Campone, Mario
    Berton-Rigaud, Dominique
    Bourbouloux, Emmanuelle
    Sophie, Sadot
    Zanetti, Alain
    Frenel, Jean-Sebastien
    BULLETIN DU CANCER, 2011, 98 (02) : 154 - 163
  • [10] Inhibition of HER2 and IGF2 in trastuzumab-resistant HER2 positive JIMT1 cells decreases cell growth and reduces activation of MAPK and AKT
    Helu, Xousaen M.
    DeLeon, Daisy
    CANCER RESEARCH, 2015, 75
12345